MedTrace Logo

Adding Nalbuphine for Control of Intrathecal Morphine Pruritus

NCT04589429 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2021-03-01

No results posted yet for this study

Summary

Intrathecal morphine causes intense itching which is very bothersome. Nalbuphine antagonizes this effect when given intravenously. This trial is to find out if nalbuphine added to intrathecal morphine has an effect on morphine related pruritus while still maintaining adequate analgesia.

Conditions

  • Pruritus
  • Pain, Postoperative
  • Nausea, Postoperative
  • Vomiting, Postoperative

Interventions

DRUG

Morphine 10 MG/ML

intrathecal morphine 300 micrograms

DRUG

Nalbuphine Hydrochloride 10 MG/ML

intrathecal nalbuphine 2mg.

Sponsors & Collaborators

  • Minia University

    lead OTHER

Principal Investigators

  • Sohair A Megalla, MD · Anesthesia and ICU department, Faculty of Medicine, Minia University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2021-03-31
Completion
2021-03-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04589429 on ClinicalTrials.gov